Zimmer Biomet: Weight Loss Drug Concerns Are Overblown

Mohammed Haneefa Nizamudeen Zimmer Biomet's (NYSE:ZBH) stock has been under pressure over the past few years, which appears to be at least in part due to concerns over the impact of GLP-1 agonists. This fear appears to be misplaced though, as it will likely be decades before any negative impact will be felt. In addition, GLP-1 agonists should provide a near-term tailwind by making more patients eligible for surgery. Joint replacement procedures have been increasing 5% annually, and even if the worst-case sc ...